Shibo Jiang

InstitutionLindsley F. Kimball Research Institute
AddressNew York
New York
United States
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 60 Covid-19 publications, with a maximum of 8 publications in February 2020
    All Publications
    Bar chart showing 406 publications over 20 distinct years, with a maximum of 38 publications in 2020
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Su S, Shao Y, Jiang S. Human challenge trials to assess the efficacy of currently approved COVID-19 vaccines against SARS-CoV-2 variants. Emerg Microbes Infect. 2021 Dec; 10(1):439-441. PMID: 33635184.
      Citations:    Fields:    Translation:Humans
    2. Hua C, Ma Q, Zhu Y, Xia S, Liu Z, Li L, Lu L, Zhong N, Liu S, Yang Z, Jiang S. Repurposing of a clinically used anti-HPV agent to prevent and treat SARS-CoV-2 infection as an intranasal formulation. Signal Transduct Target Ther. 2021 08 26; 6(1):318. PMID: 34446694.
      Citations: 1     Translation:Humans
    3. Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q. A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases. Acta Pharm Sin B. 2021 Aug 02. PMID: 34367893.
      Citations:    
    4. Xia S, Lan Q, Zhu Y, Wang C, Xu W, Li Y, Wang L, Jiao F, Zhou J, Hua C, Wang Q, Cai X, Wu Y, Gao J, Liu H, Sun G, Münch J, Kirchhoff F, Yuan Z, Xie Y, Sun F, Jiang S, Lu L. Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation. Signal Transduct Target Ther. 2021 07 29; 6(1):288. PMID: 34326308.
      Citations: 6     Translation:HumansAnimalsCells
    5. Cai Y, Xu W, Tang J, Cao N, Lan Q, Lu L, Jiang S. A bivalent protein targeting glycans and HR1 domain in spike protein potently inhibited infection of SARS-CoV-2 and other human coronaviruses. Cell Biosci. 2021 Jul 08; 11(1):128. PMID: 34238357.
      Citations:    
    6. Xiang R, Yu Z, Wang Y, Wang L, Huo S, Li Y, Liang R, Hao Q, Ying T, Gao Y, Yu F, Jiang S. Recent advances in developing small-molecule inhibitors against SARS-CoV-2. Acta Pharm Sin B. 2021 Jul 02. PMID: 34249607.
      Citations: 4     
    7. Zhang Q, Xiang R, Huo S, Zhou Y, Jiang S, Wang Q, Yu F. Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. Signal Transduct Target Ther. 2021 06 11; 6(1):233. PMID: 34117216.
      Citations: 11     Translation:Humans
    8. Shen H, Cai Y, Zhang H, Wu J, Ye L, Yang P, Lin X, Jiang S, Liao M. Anti-SARS-CoV-2 IgY Isolated from Egg Yolks of Hens Immunized with Inactivated SARS-CoV-2 for Immunoprophylaxis of COVID-19. Virol Sin. 2021 10; 36(5):1080-1082. PMID: 34019233.
      Citations: 2     Fields:    Translation:HumansAnimals
    9. Lan Q, Pu J, Cai Y, Zhou J, Wang L, Jiao F, Xu W, Wang Q, Xia S, Lu L, Jiang S. Lipopeptide-based pan-CoV fusion inhibitors potently inhibit HIV-1 infection. Microbes Infect. 2021 Sep-Oct; 23(8):104840. PMID: 34022374.
      Citations:    Fields:    Translation:HumansCells
    10. Su S, Liu Z, Jiang S. Double insult: flu bug enhances SARS-CoV-2 infectivity. Cell Res. 2021 05; 31(5):491-492. PMID: 33758364.
      Citations:    Fields:    Translation:HumansCells
    11. Wang C, Xia S, Wang X, Li Y, Wang H, Xiang R, Jiang Q, Lan Q, Liang R, Li Q, Huo S, Lu L, Wang Q, Yu F, Liu K, Jiang S. Supercoiling Structure-Based Design of a Trimeric Coiled-Coil Peptide with High Potency against HIV-1 and Human ß-Coronavirus Infection. J Med Chem. 2022 02 24; 65(4):2809-2819. PMID: 33929200.
      Citations:    Fields:    
    12. Li C, Tian X, Jia X, Wan J, Lu L, Jiang S, Lan F, Lu Y, Wu Y, Ying T. The impact of receptor-binding domain natural mutations on antibody recognition of SARS-CoV-2. Signal Transduct Target Ther. 2021 03 23; 6(1):132. PMID: 33758169.
      Citations: 11     Translation:HumansCells
    13. Lu L, Su S, Yang H, Jiang S. Antivirals with common targets against highly pathogenic viruses. Cell. 2021 03 18; 184(6):1604-1620. PMID: 33740455.
      Citations: 7     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    14. Zhao H, To KKW, Lam H, Zhou X, Chan JF, Peng Z, Lee ACY, Cai J, Chan WM, Ip JD, Chan CC, Yeung ML, Zhang AJ, Chu AWH, Jiang S, Yuen KY. Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2. Nat Commun. 2021 03 09; 12(1):1517. PMID: 33750821.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    15. Cao M, Su X, Jiang S. Broad-Spectrum Anti-coronavirus Vaccines and Therapeutics to Combat the Current COVID-19 Pandemic and Future Coronavirus Disease Outbreaks. Stem Cell Reports. 2021 03 09; 16(3):398-411. PMID: 33691145.
      Citations: 3     Fields:    Translation:HumansAnimalsPHPublic Health
    16. Dai M, Li H, Yan N, Huang J, Zhao L, Xu S, Wu J, Jiang S, Pan C, Liao M. Long-term Survival of SARS-CoV-2 on Salmon as a Source for International Transmission. J Infect Dis. 2021 02 13; 223(3):537-539. PMID: 33179031.
      Citations: 6     Fields:    Translation:HumansAnimals
    17. Li F, Han M, Dai P, Xu W, He J, Tao X, Wu Y, Tong X, Xia X, Guo W, Zhou Y, Li Y, Zhu Y, Zhang X, Liu Z, Aji R, Cai X, Li Y, Qu D, Chen Y, Jiang S, Wang Q, Ji H, Xie Y, Sun Y, Lu L, Gao D. Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide. Nat Commun. 2021 02 08; 12(1):866. PMID: 33558541.
      Citations: 17     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    18. Xu W, Su S, Jiang S. Ring vaccination of COVID-19 vaccines in medium- and high-risk areas of countries with low incidence of SARS-CoV-2 infection. Clin Transl Med. 2021 02; 11(2):e331. PMID: 33634979.
      Citations: 2     Translation:HumansPHPublic Health
    19. Zhou Y, Liu Z, Li S, Xu W, Zhang Q, Silva IT, Li C, Wu Y, Jiang Q, Liu Z, Wang Q, Guo Y, Wu J, Gu C, Cai X, Qu D, Mayer CT, Wang X, Jiang S, Ying T, Yuan Z, Xie Y, Wen Y, Lu L, Wang Q. Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. Cell Rep. 2021 02 02; 34(5):108699. PMID: 33485405.
      Citations: 25     Fields:    Translation:HumansCells
    20. Wang X, Xia S, Zhu Y, Lu L, Jiang S. Pan-coronavirus fusion inhibitors as the hope for today and tomorrow. Protein Cell. 2021 02; 12(2):84-88. PMID: 33420956.
      Citations: 6     Fields:    Translation:HumansCells
    21. Wang S, Qiu Z, Hou Y, Deng X, Xu W, Zheng T, Wu P, Xie S, Bian W, Zhang C, Sun Z, Liu K, Shan C, Lin A, Jiang S, Xie Y, Zhou Q, Lu L, Huang J, Li X. AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells. Cell Res. 2021 02; 31(2):126-140. PMID: 33420426.
      Citations: 74     Fields:    Translation:HumansCells
    22. Su S, Wang Q, Jiang S. Facing the challenge of viral mutations in the age of pandemic: Developing highly potent, broad-spectrum, and safe COVID-19 vaccines and therapeutics. Clin Transl Med. 2021 01; 11(1):e284. PMID: 33463059.
      Citations: 3     Translation:HumansPHPublic Health
    23. Jiang S, Zhang X, Yang Y, Hotez PJ, Du L. Neutralizing antibodies for the treatment of COVID-19. Nat Biomed Eng. 2020 12; 4(12):1134-1139. PMID: 33293725.
      Citations: 33     Fields:    Translation:HumansPHPublic Health
    24. Liu Z, Xu W, Xia S, Gu C, Wang X, Wang Q, Zhou J, Wu Y, Cai X, Qu D, Ying T, Xie Y, Lu L, Yuan Z, Jiang S. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Signal Transduct Target Ther. 2020 11 27; 5(1):282. PMID: 33247109.
      Citations: 34     Translation:HumansAnimalsCellsPHPublic Health
    25. Guo L, Bi W, Wang X, Xu W, Yan R, Zhang Y, Zhao K, Li Y, Zhang M, Cai X, Jiang S, Xie Y, Zhou Q, Lu L, Dang B. Engineered trimeric ACE2 binds viral spike protein and locks it in "Three-up" conformation to potently inhibit SARS-CoV-2 infection. Cell Res. 2021 01; 31(1):98-100. PMID: 33177651.
      Citations: 24     Fields:    Translation:HumansCells
    26. Su S, Du L, Jiang S. Learning from the past: development of safe and effective COVID-19 vaccines. Nat Rev Microbiol. 2021 03; 19(3):211-219. PMID: 33067570.
      Citations: 33     Fields:    Translation:Humans
    27. Cai Y, Xu W, Gu C, Cai X, Qu D, Lu L, Xie Y, Jiang S. Griffithsin with A Broad-Spectrum Antiviral Activity by Binding Glycans in Viral Glycoprotein Exhibits Strong Synergistic Effect in Combination with A Pan-Coronavirus Fusion Inhibitor Targeting SARS-CoV-2 Spike S2 Subunit. Virol Sin. 2020 12; 35(6):857-860. PMID: 33052520.
      Citations: 11     Fields:    Translation:HumansCells
    28. Rao L, Xia S, Xu W, Tian R, Yu G, Gu C, Pan P, Meng QF, Cai X, Qu D, Lu L, Xie Y, Jiang S, Chen X. Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines. Proc Natl Acad Sci U S A. 2020 11 03; 117(44):27141-27147. PMID: 33024017.
      Citations: 43     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    29. Yang C, Pan X, Xu X, Cheng C, Huang Y, Li L, Jiang S, Xu W, Xiao G, Liu S. Salvianolic acid C potently inhibits SARS-CoV-2 infection by blocking the formation of six-helix bundle core of spike protein. Signal Transduct Target Ther. 2020 10 06; 5(1):220. PMID: 33024075.
      Citations: 9     Translation:HumansAnimalsCellsPHPublic Health
    30. Wu F, Liu M, Wang A, Lu L, Wang Q, Gu C, Chen J, Wu Y, Xia S, Ling Y, Zhang Y, Xun J, Zhang R, Xie Y, Jiang S, Zhu T, Lu H, Wen Y, Huang J. Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China. JAMA Intern Med. 2020 10 01; 180(10):1356-1362. PMID: 32808970.
      Citations: 85     Fields:    Translation:HumansCellsPHPublic Health
    31. Yu F, Xiang R, Deng X, Wang L, Yu Z, Tian S, Liang R, Li Y, Ying T, Jiang S. Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2. Signal Transduct Target Ther. 2020 09 22; 5(1):212. PMID: 32963228.
      Citations: 29     Translation:HumansCellsPHPublic Health
    32. Chen WH, Tao X, Agrawal AS, Algaissi A, Peng BH, Pollet J, Strych U, Bottazzi ME, Hotez PJ, Lustigman S, Du L, Jiang S, Tseng CK. Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement. Vaccine. 2020 11 03; 38(47):7533-7541. PMID: 33039209.
      Citations: 24     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    33. Jiang S, Zhang X, Du L. Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2. Expert Opin Ther Targets. 2021 06; 25(6):415-421. PMID: 32941780.
      Citations: 9     Fields:    Translation:Humans
    34. Jiang S, Du L. Effect of Low-Pathogenic Human Coronavirus-Specific Antibodies on SARS-CoV-2. Trends Immunol. 2020 10; 41(10):853-854. PMID: 32863133.
      Citations: 4     Fields:    Translation:HumansCellsPHPublic Health
    35. Tai W, Zhang X, Drelich A, Shi J, Hsu JC, Luchsinger L, Hillyer CD, Tseng CK, Jiang S, Du L. A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2. Cell Res. 2020 10; 30(10):932-935. PMID: 32759966.
      Citations: 36     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    36. Wang X, Xu W, Hu G, Xia S, Sun Z, Liu Z, Xie Y, Zhang R, Jiang S, Lu L. Retraction Note to: SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion. Cell Mol Immunol. 2020 08; 17(8):894. PMID: 32651469.
      Citations: 17     Fields:    
    37. Gu H, Chen Q, Yang G, He L, Fan H, Deng YQ, Wang Y, Teng Y, Zhao Z, Cui Y, Li Y, Li XF, Li J, Zhang NN, Yang X, Chen S, Guo Y, Zhao G, Wang X, Luo DY, Wang H, Yang X, Li Y, Han G, He Y, Zhou X, Geng S, Sheng X, Jiang S, Sun S, Qin CF, Zhou Y. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. Science. 2020 09 25; 369(6511):1603-1607. PMID: 32732280.
      Citations: 205     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    38. Xia S, Lan Q, Su S, Wang X, Xu W, Liu Z, Zhu Y, Wang Q, Lu L, Jiang S. The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin. Signal Transduct Target Ther. 2020 06 12; 5(1):92. PMID: 32532959.
      Citations: 91     Translation:HumansCells
    39. Wang X, Xia S, Wang Q, Xu W, Li W, Lu L, Jiang S. Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases. Int J Mol Sci. 2020 May 28; 21(11). PMID: 32481690.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    40. Su S, Jiang S. A suspicious role of interferon in the pathogenesis of SARS-CoV-2 by enhancing expression of ACE2. Signal Transduct Target Ther. 2020 05 21; 5(1):71. PMID: 32435059.
      Citations: 8     Translation:HumansCellsPHPublic Health
    41. Wu Y, Li C, Xia S, Tian X, Kong Y, Wang Z, Gu C, Zhang R, Tu C, Xie Y, Yang Z, Lu L, Jiang S, Ying T. Identification of Human Single-Domain Antibodies against SARS-CoV-2. Cell Host Microbe. 2020 06 10; 27(6):891-898.e5. PMID: 32413276.
      Citations: 89     Fields:    Translation:HumansCells
    42. Tai W, Zhang X, He Y, Jiang S, Du L. Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2. Antiviral Res. 2020 07; 179:104820. PMID: 32405117.
      Citations: 35     Fields:    Translation:HumansCellsPHPublic Health
    43. Ma C, Su S, Wang J, Wei L, Du L, Jiang S. From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development. Microbes Infect. 2020 Jul - Aug; 22(6-7):245-253. PMID: 32437926.
      Citations: 15     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    44. Zhang N, Li C, Hu Y, Li K, Liang J, Wang L, Du L, Jiang S. Current development of COVID-19 diagnostics, vaccines and therapeutics. Microbes Infect. 2020 Jul - Aug; 22(6-7):231-235. PMID: 32387332.
      Citations: 19     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    45. Jiang S, Hillyer C, Du L. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses: (Trends in Immunology 41, 355-359; 2020). Trends Immunol. 2020 06; 41(6):545. PMID: 32362491.
      Citations: 44     Fields:    
    46. Wang X, Xu W, Hu G, Xia S, Sun Z, Liu Z, Xie Y, Zhang R, Jiang S, Lu L. RETRACTED ARTICLE: SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion. Cell Mol Immunol. 2020 04 07. PMID: 32265513.
      Citations: 105     Fields:    
    47. Jiang S, Hillyer C, Du L. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses. Trends Immunol. 2020 05; 41(5):355-359. PMID: 32249063.
      Citations: 287     Fields:    Translation:HumansCellsPHPublic Health
    48. Liu Z, Xia S, Wang X, Lan Q, Xu W, Wang Q, Jiang S, Lu L. Inefficiency of Sera from Mice Treated with Pseudotyped SARS-CoV to Neutralize 2019-nCoV Infection. Virol Sin. 2020 06; 35(3):340-343. PMID: 32236815.
      Citations: 6     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    49. Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 2020 Apr; 30(4):343-355. PMID: 32231345.
      Citations: 417     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    50. Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, Zhou Y, Du L. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020 06; 17(6):613-620. PMID: 32203189.
      Citations: 500     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    51. Jiang S. Don't rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees. Nature. 2020 03; 579(7799):321. PMID: 32179860.
      Citations: 69     Fields:    Translation:HumansCells
    52. Wang N, Shang J, Jiang S, Du L. Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses. Front Microbiol. 2020; 11:298. PMID: 32265848.
      Citations: 109     
    53. Jiang S, Shi Z, Shu Y, Song J, Gao GF, Tan W, Guo D. A distinct name is needed for the new coronavirus. Lancet. 2020 03 21; 395(10228):949. PMID: 32087125.
      Citations: 86     Fields:    Translation:HumansCells
    54. Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, Lu L, Jiang S, Yang Z, Wu Y, Ying T. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 2020; 9(1):382-385. PMID: 32065055.
      Citations: 534     Fields:    Translation:HumansCells
    55. Jiang S, Shi ZL. The First Disease X is Caused by a Highly Transmissible Acute Respiratory Syndrome Coronavirus. Virol Sin. 2020 Jun; 35(3):263-265. PMID: 32060789.
      Citations: 28     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    56. Xia S, Zhu Y, Liu M, Lan Q, Xu W, Wu Y, Ying T, Liu S, Shi Z, Jiang S, Lu L. Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell Mol Immunol. 2020 07; 17(7):765-767. PMID: 32047258.
      Citations: 201     Fields:    Translation:HumansCellsPHPublic Health
    57. Jiang S, Xia S, Ying T, Lu L. A novel coronavirus (2019-nCoV) causing pneumonia-associated respiratory syndrome. Cell Mol Immunol. 2020 05; 17(5):554. PMID: 32024976.
      Citations: 54     Fields:    Translation:HumansCellsPHPublic Health
    58. Zhang N, Wang L, Deng X, Liang R, Su M, He C, Hu L, Su Y, Ren J, Yu F, Du L, Jiang S. Recent advances in the detection of respiratory virus infection in humans. J Med Virol. 2020 04; 92(4):408-417. PMID: 31944312.
      Citations: 114     Fields:    Translation:HumansCells
    59. Yu F, Du L, Ojcius DM, Pan C, Jiang S. Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. Microbes Infect. 2020 03; 22(2):74-79. PMID: 32017984.
      Citations: 129     Fields:    Translation:HumansCells
    60. Jiang S, Du L, Shi Z. An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies. Emerg Microbes Infect. 2020; 9(1):275-277. PMID: 32005086.
      Citations: 108     Fields:    Translation:HumansAnimalsCells
    61. Xia S, Yan L, Xu W, Agrawal AS, Algaissi A, Tseng CK, Wang Q, Du L, Tan W, Wilson IA, Jiang S, Yang B, Lu L. A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci Adv. 2019 04; 5(4):eaav4580. PMID: 30989115.
      Citations: 146     Fields:    Translation:HumansAnimalsCells
    62. Xia S, Lan Q, Pu J, Wang C, Liu Z, Xu W, Wang Q, Liu H, Jiang S, Lu L. Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4. Viruses. 2019 01 14; 11(1). PMID: 30646495.
      Citations: 11     Fields:    Translation:AnimalsCells
    63. Zhou Y, Yang Y, Huang J, Jiang S, Du L. Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain. Viruses. 2019 01 14; 11(1). PMID: 30646569.
      Citations: 42     Fields:    Translation:HumansAnimalsCells
    64. Wang C, Hua C, Xia S, Li W, Lu L, Jiang S. Combining a Fusion Inhibitory Peptide Targeting the MERS-CoV S2 Protein HR1 Domain and a Neutralizing Antibody Specific for the S1 Protein Receptor-Binding Domain (RBD) Showed Potent Synergism against Pseudotyped MERS-CoV with or without Mutations in RBD. Viruses. 2019 01 06; 11(1). PMID: 30621343.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    65. Liang R, Wang L, Zhang N, Deng X, Su M, Su Y, Hu L, He C, Ying T, Jiang S, Yu F. Development of Small-Molecule MERS-CoV Inhibitors. Viruses. 2018 12 17; 10(12). PMID: 30562987.
      Citations: 26     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    66. Wang C, Zhao L, Xia S, Zhang T, Cao R, Liang G, Li Y, Meng G, Wang W, Shi W, Zhong W, Jiang S, Liu K. De Novo Design of a-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. J Med Chem. 2018 10 11; 61(19):8734-8745. PMID: 30192544.
      Citations: 13     Fields:    Translation:HumansCells
    67. Zhao G, He L, Sun S, Qiu H, Tai W, Chen J, Li J, Chen Y, Guo Y, Wang Y, Shang J, Ji K, Fan R, Du E, Jiang S, Li F, Du L, Zhou Y. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV. J Virol. 2018 09 15; 92(18). PMID: 29950421.
      Citations: 33     Fields:    Translation:HumansAnimalsCells
    68. Fan C, Wu X, Liu Q, Li Q, Liu S, Lu J, Yang Y, Cao Y, Huang W, Liang C, Ying T, Jiang S, Wang Y. A Human DPP4-Knockin Mouse's Susceptibility to Infection by Authentic and Pseudotyped MERS-CoV. Viruses. 2018 08 23; 10(9). PMID: 30142928.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    69. Zhou Y, Jiang S, Du L. Prospects for a MERS-CoV spike vaccine. Expert Rev Vaccines. 2018 08; 17(8):677-686. PMID: 30058403.
      Citations: 51     Fields:    Translation:HumansAnimalsCells
    70. Jiang Y, Zhao G, Song N, Li P, Chen Y, Guo Y, Li J, Du L, Jiang S, Guo R, Sun S, Zhou Y. Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV. Emerg Microbes Infect. 2018 Apr 24; 7(1):77. PMID: 29691378.
      Citations: 95     Fields:    Translation:HumansAnimalsCells
    71. Nyon MP, Du L, Tseng CK, Seid CA, Pollet J, Naceanceno KS, Agrawal A, Algaissi A, Peng BH, Tai W, Jiang S, Bottazzi ME, Strych U, Hotez PJ. Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen. Vaccine. 2018 03 27; 36(14):1853-1862. PMID: 29496347.
      Citations: 28     Fields:    Translation:AnimalsCells
    72. Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K. Discovery of Hydrocarbon-Stapled Short a-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. J Med Chem. 2018 03 08; 61(5):2018-2026. PMID: 29442512.
      Citations: 16     Fields:    Translation:HumansCells
    73. Xia S, Xu W, Wang Q, Wang C, Hua C, Li W, Lu L, Jiang S. Peptide-Based Membrane Fusion Inhibitors Targeting HCoV-229E Spike Protein HR1 and HR2 Domains. Int J Mol Sci. 2018 Feb 06; 19(2). PMID: 29415501.
      Citations: 24     Fields:    Translation:HumansAnimalsCells
    74. Wang X, Zou P, Wu F, Lu L, Jiang S. Development of small-molecule viral inhibitors targeting various stages of the life cycle of emerging and re-emerging viruses. Front Med. 2017 Dec; 11(4):449-461. PMID: 29170916.
      Citations: 7     Fields:    Translation:Humans
    75. Zeng LP, Ge XY, Peng C, Tai W, Jiang S, Du L, Shi ZL. Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses. Sci China Life Sci. 2017 12; 60(12):1399-1402. PMID: 29134417.
      Citations: 14     Fields:    Translation:AnimalsCells
    76. Wang Y, Tai W, Yang J, Zhao G, Sun S, Tseng CK, Jiang S, Zhou Y, Du L, Gao J. Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection. Hum Vaccin Immunother. 2017 07 03; 13(7):1615-1624. PMID: 28277821.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    77. Du L, Yang Y, Zhou Y, Lu L, Li F, Jiang S. MERS-CoV spike protein: a key target for antivirals. Expert Opin Ther Targets. 2017 Feb; 21(2):131-143. PMID: 27936982.
      Citations: 99     Fields:    Translation:HumansAnimalsCells
    78. Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors. J Virol. 2017 Jan 01; 91(1). PMID: 27795416.
      Citations: 13     Fields:    Translation:HumansCells
    79. Tai W, Wang Y, Fett CA, Zhao G, Li F, Perlman S, Jiang S, Zhou Y, Du L. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants. J Virol. 2017 Jan 01; 91(1). PMID: 27795425.
      Citations: 36     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    80. Du L, Tai W, Yang Y, Zhao G, Zhu Q, Sun S, Liu C, Tao X, Tseng CK, Perlman S, Jiang S, Zhou Y, Li F. Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines. Nat Commun. 2016 11 22; 7:13473. PMID: 27874853.
      Citations: 57     Fields:    Translation:HumansAnimalsCells
    81. Tai W, Zhao G, Sun S, Guo Y, Wang Y, Tao X, Tseng CK, Li F, Jiang S, Du L, Zhou Y. A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection. Virology. 2016 12; 499:375-382. PMID: 27750111.
      Citations: 46     Fields:    Translation:HumansAnimalsCells
    82. Liu C, Ma Y, Yang Y, Zheng Y, Shang J, Zhou Y, Jiang S, Du L, Li J, Li F. Cell Entry of Porcine Epidemic Diarrhea Coronavirus Is Activated by Lysosomal Proteases. J Biol Chem. 2016 Nov 18; 291(47):24779-24786. PMID: 27729455.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    83. Agrawal AS, Ying T, Tao X, Garron T, Algaissi A, Wang Y, Wang L, Peng BH, Jiang S, Dimitrov DS, Tseng CT. Passive Transfer of A Germline-like Neutralizing Human Monoclonal Antibody Protects Transgenic Mice Against Lethal Middle East Respiratory Syndrome Coronavirus Infection. Sci Rep. 2016 08 19; 6:31629. PMID: 27538452.
      Citations: 25     Fields:    Translation:HumansAnimalsCells
    84. Du L, Tai W, Zhou Y, Jiang S. Vaccines for the prevention against the threat of MERS-CoV. Expert Rev Vaccines. 2016 09; 15(9):1123-34. PMID: 26985862.
      Citations: 39     Fields:    Translation:HumansAnimalsCells
    85. Zhao G, Jiang Y, Qiu H, Gao T, Zeng Y, Guo Y, Yu H, Li J, Kou Z, Du L, Tan W, Jiang S, Sun S, Zhou Y. Multi-Organ Damage in Human Dipeptidyl Peptidase 4 Transgenic Mice Infected with Middle East Respiratory Syndrome-Coronavirus. PLoS One. 2015; 10(12):e0145561. PMID: 26701103.
      Citations: 44     Fields:    Translation:HumansAnimalsCells
    86. Xia S, Wang Q, Liu SW, Lu L, Jiang SB. [Development of peptidic MERS-CoV entry inhibitors]. Yao Xue Xue Bao. 2015 Dec; 50(12):1513-9. PMID: 27169270.
      Citations: 2     Fields:    Translation:HumansCells
    87. Zeng XY, Lu L, Jiang SB, Liu SW. [Small molecular agents against MERS-CoV infection]. Yao Xue Xue Bao. 2015 Dec; 50(12):1520-6. PMID: 27169271.
      Citations:    Fields:    Translation:HumansCells
    88. Wang X, Chen J, Shi D, Shi H, Zhang X, Yuan J, Jiang S, Feng L. Immunogenicity and antigenic relationships among spike proteins of porcine epidemic diarrhea virus subtypes G1 and G2. Arch Virol. 2016 Mar; 161(3):537-47. PMID: 26611909.
      Citations: 16     Fields:    Translation:AnimalsCellsPHPublic Health
    89. Tao X, Garron T, Agrawal AS, Algaissi A, Peng BH, Wakamiya M, Chan TS, Lu L, Du L, Jiang S, Couch RB, Tseng CT. Characterization and Demonstration of the Value of a Lethal Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease. J Virol. 2016 01 01; 90(1):57-67. PMID: 26446606.
      Citations: 35     Fields:    Translation:HumansAnimalsCells
    90. Du L, Jiang S. Middle East respiratory syndrome: current status and future prospects for vaccine development. Expert Opin Biol Ther. 2015; 15(11):1647-51. PMID: 26414077.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    91. Ying T, Prabakaran P, Du L, Shi W, Feng Y, Wang Y, Wang L, Li W, Jiang S, Dimitrov DS, Zhou T. Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody. Nat Commun. 2015 Sep 15; 6:8223. PMID: 26370782.
      Citations: 59     Fields:    Translation:HumansCells
    92. Dimitrov DS, Jiang S, Ying T, Tseng CT, Zhang L, Yuen KY. No evidence for a superior platform to develop therapeutic antibodies rapidly in response to MERS-CoV and other emerging viruses. Proc Natl Acad Sci U S A. 2015 Sep 15; 112(37):E5115. PMID: 26318165.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    93. Lu L, Xia S, Ying T, Jiang S. Urgent development of effective therapeutic and prophylactic agents to control the emerging threat of Middle East respiratory syndrome (MERS). Emerg Microbes Infect. 2015 Jun 17; 4:e37. PMID: 26954884.
      Citations: 6     Fields:    Translation:HumansCells
    94. Yang Y, Liu C, Du L, Jiang S, Shi Z, Baric RS, Li F. Two Mutations Were Critical for Bat-to-Human Transmission of Middle East Respiratory Syndrome Coronavirus. J Virol. 2015 Sep; 89(17):9119-23. PMID: 26063432.
      Citations: 58     Fields:    Translation:HumansAnimalsCells
    95. Channappanavar R, Lu L, Xia S, Du L, Meyerholz DK, Perlman S, Jiang S. Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection. J Infect Dis. 2015 Dec 15; 212(12):1894-903. PMID: 26164863.
      Citations: 46     Fields:    Translation:HumansAnimalsCells
    96. Liu C, Tang J, Ma Y, Liang X, Yang Y, Peng G, Qi Q, Jiang S, Li J, Du L, Li F. Receptor usage and cell entry of porcine epidemic diarrhea coronavirus. J Virol. 2015 Jun; 89(11):6121-5. PMID: 25787280.
      Citations: 79     Fields:    Translation:HumansAnimalsCells
    97. Zhang N, Channappanavar R, Ma C, Wang L, Tang J, Garron T, Tao X, Tasneem S, Lu L, Tseng CT, Zhou Y, Perlman S, Jiang S, Du L. Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. Cell Mol Immunol. 2016 Mar; 13(2):180-90. PMID: 25640653.
      Citations: 65     Fields:    Translation:HumansAnimalsCells
    98. Tang J, Zhang N, Tao X, Zhao G, Guo Y, Tseng CT, Jiang S, Du L, Zhou Y. Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus. Hum Vaccin Immunother. 2015; 11(5):1244-50. PMID: 25874632.
      Citations: 41     Fields:    Translation:HumansAnimalsCells
    99. Ying T, Li H, Lu L, Dimitrov DS, Jiang S. Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections. Microbes Infect. 2015 Feb; 17(2):142-8. PMID: 25456101.
      Citations: 24     Fields:    Translation:HumansCellsPHPublic Health
    100. Zhang N, Tang J, Lu L, Jiang S, Du L. Receptor-binding domain-based subunit vaccines against MERS-CoV. Virus Res. 2015 Apr 16; 202:151-9. PMID: 25445336.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    101. Liu Q, Xia S, Sun Z, Wang Q, Du L, Lu L, Jiang S. Testing of Middle East respiratory syndrome coronavirus replication inhibitors for the ability to block viral entry. Antimicrob Agents Chemother. 2015 Jan; 59(1):742-4. PMID: 25331705.
      Citations: 23     Fields:    Translation:HumansCells
    102. Xia S, Liu Q, Wang Q, Sun Z, Su S, Du L, Ying T, Lu L, Jiang S. Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein. Virus Res. 2014 Dec 19; 194:200-10. PMID: 25451066.
      Citations: 46     Fields:    Translation:HumansCells
    103. Ma C, Wang L, Tao X, Zhang N, Yang Y, Tseng CK, Li F, Zhou Y, Jiang S, Du L. Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments--the importance of immunofocusing in subunit vaccine design. Vaccine. 2014 Oct 21; 32(46):6170-6176. PMID: 25240756.
      Citations: 67     Fields:    Translation:HumansAnimalsCells
    104. Yang Y, Du L, Liu C, Wang L, Ma C, Tang J, Baric RS, Jiang S, Li F. Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus. Proc Natl Acad Sci U S A. 2014 Aug 26; 111(34):12516-21. PMID: 25114257.
      Citations: 112     Fields:    Translation:HumansAnimalsCells
    105. Hotez PJ, Bottazzi ME, Tseng CT, Zhan B, Lustigman S, Du L, Jiang S. Calling for rapid development of a safe and effective MERS vaccine. Microbes Infect. 2014 Jul; 16(7):529-31. PMID: 24931059.
      Citations: 18     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    106. Ying T, Du L, Ju TW, Prabakaran P, Lau CC, Lu L, Liu Q, Wang L, Feng Y, Wang Y, Zheng BJ, Yuen KY, Jiang S, Dimitrov DS. Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J Virol. 2014 Jul; 88(14):7796-805. PMID: 24789777.
      Citations: 107     Fields:    Translation:HumansCells
    107. Zhang N, Jiang S, Du L. Current advancements and potential strategies in the development of MERS-CoV vaccines. Expert Rev Vaccines. 2014 Jun; 13(6):761-74. PMID: 24766432.
      Citations: 70     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    108. Du L, Zhao G, Yang Y, Qiu H, Wang L, Kou Z, Tao X, Yu H, Sun S, Tseng CT, Jiang S, Li F, Zhou Y. A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. J Virol. 2014 Jun; 88(12):7045-53. PMID: 24719424.
      Citations: 69     Fields:    Translation:HumansAnimalsCells
    109. Ma C, Li Y, Wang L, Zhao G, Tao X, Tseng CT, Zhou Y, Du L, Jiang S. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines. Vaccine. 2014 Apr 11; 32(18):2100-8. PMID: 24560617.
      Citations: 74     Fields:    Translation:HumansAnimalsCells
    110. Lu L, Liu Q, Zhu Y, Chan KH, Qin L, Li Y, Wang Q, Chan JF, Du L, Yu F, Ma C, Ye S, Yuen KY, Zhang R, Jiang S. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun. 2014; 5:3067. PMID: 24473083.
      Citations: 157     Fields:    Translation:HumansCells
    111. Chen WH, Du L, Chag SM, Ma C, Tricoche N, Tao X, Seid CA, Hudspeth EM, Lustigman S, Tseng CT, Bottazzi ME, Hotez PJ, Zhan B, Jiang S. Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate. Hum Vaccin Immunother. 2014; 10(3):648-58. PMID: 24355931.
      Citations: 49     Fields:    Translation:AnimalsCells
    112. Du L, Kou Z, Ma C, Tao X, Wang L, Zhao G, Chen Y, Yu F, Tseng CT, Zhou Y, Jiang S. A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PLoS One. 2013; 8(12):e81587. PMID: 24324708.
      Citations: 92     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    113. Zhao G, Du L, Ma C, Li Y, Li L, Poon VK, Wang L, Yu F, Zheng BJ, Jiang S, Zhou Y. A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV. Virol J. 2013 Aug 26; 10:266. PMID: 23978242.
      Citations: 55     Fields:    Translation:HumansAnimalsCells
    114. Zhu X, Liu Q, Du L, Lu L, Jiang S. Receptor-binding domain as a target for developing SARS vaccines. J Thorac Dis. 2013 Aug; 5 Suppl 2:S142-8. PMID: 23977435.
      Citations: 36     
    115. Du L, Zhao G, Kou Z, Ma C, Sun S, Poon VK, Lu L, Wang L, Debnath AK, Zheng BJ, Zhou Y, Jiang S. Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J Virol. 2013 Sep; 87(17):9939-42. PMID: 23824801.
      Citations: 96     Fields:    Translation:HumansAnimalsCells
    116. Lu L, Liu Q, Du L, Jiang S. Middle East respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread. Microbes Infect. 2013 Jul-Aug; 15(8-9):625-9. PMID: 23791956.
      Citations: 40     Fields:    Translation:HumansCellsPHPublic Health
    117. Du L, Ma C, Jiang S. Antibodies induced by receptor-binding domain in spike protein of SARS-CoV do not cross-neutralize the novel human coronavirus hCoV-EMC. J Infect. 2013 Oct; 67(4):348-50. PMID: 23685240.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    118. Jiang S, Lu L, Du L, Debnath AK. Putative conformations of the receptor-binding domain in S protein of hCoV-EMC in complex with its receptor dipeptidyl peptidase-4. J Infect. 2013 Aug; 67(2):156-8. PMID: 23603488.
      Citations: 4     Fields:    Translation:HumansCells
    119. Jiang S, Lu L, Du L, Debnath AK. A predicted receptor-binding and critical neutralizing domain in S protein of the novel human coronavirus HCoV-EMC. J Infect. 2013 May; 66(5):464-6. PMID: 23266463.
      Citations: 28     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    120. Jiang S, Bottazzi ME, Du L, Lustigman S, Tseng CT, Curti E, Jones K, Zhan B, Hotez PJ. Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. Expert Rev Vaccines. 2012 Dec; 11(12):1405-13. PMID: 23252385.
      Citations: 58     Fields:    Translation:HumansAnimalsCells
    121. Jiang S, Lu L, Liu Q, Xu W, Du L. Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines. Emerg Microbes Infect. 2012 Aug; 1(8):e13. PMID: 26038424.
      Citations: 21     Fields:    
    122. Wang J, Tricoche N, Du L, Hunter M, Zhan B, Goud G, Didier ES, Liu J, Lu L, Marx PA, Jiang S, Lustigman S. The adjuvanticity of an O. volvulus-derived rOv-ASP-1 protein in mice using sequential vaccinations and in non-human primates. PLoS One. 2012; 7(5):e37019. PMID: 22615877.
      Citations: 18     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    123. Du L, Zhang X, Liu J, Jiang S. Protocol for recombinant RBD-based SARS vaccines: protein preparation, animal vaccination and neutralization detection. J Vis Exp. 2011 May 02; (51). PMID: 21587153.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    124. Cao Z, Liu L, Du L, Zhang C, Jiang S, Li T, He Y. Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients. Virol J. 2010 Nov 04; 7:299. PMID: 21047436.
      Citations: 41     Fields:    Translation:HumansAnimalsCells
    125. Du L, Zhao G, Chan CC, Li L, He Y, Zhou Y, Zheng BJ, Jiang S. A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity. Viral Immunol. 2010 Apr; 23(2):211-9. PMID: 20374001.
      Citations: 24     Fields:    Translation:AnimalsCells
    126. Du L, Zhao G, Chan CC, Sun S, Chen M, Liu Z, Guo H, He Y, Zhou Y, Zheng BJ, Jiang S. Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. Virology. 2009 Oct 10; 393(1):144-50. PMID: 19683779.
      Citations: 63     Fields:    Translation:AnimalsCells
    127. Du L, Zhao G, Li L, He Y, Zhou Y, Zheng BJ, Jiang S. Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells. Biochem Biophys Res Commun. 2009 Jul 10; 384(4):486-90. PMID: 19422787.
      Citations: 28     Fields:    Translation:AnimalsCellsPHPublic Health
    128. He Y, Barker SJ, MacDonald AJ, Yu Y, Cao L, Li J, Parhar R, Heck S, Hartmann S, Golenbock DT, Jiang S, Libri NA, Semper AE, Rosenberg WM, Lustigman S. Recombinant Ov-ASP-1, a Th1-biased protein adjuvant derived from the helminth Onchocerca volvulus, can directly bind and activate antigen-presenting cells. J Immunol. 2009 Apr 01; 182(7):4005-16. PMID: 19299698.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    129. Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009 Mar; 7(3):226-36. PMID: 19198616.
      Citations: 606     Fields:    Translation:HumansAnimalsCells
    130. Du L, Zhao G, Lin Y, Chan C, He Y, Jiang S, Wu C, Jin DY, Yuen KY, Zhou Y, Zheng BJ. Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection. Vaccine. 2008 Mar 20; 26(13):1644-51. PMID: 18289745.
      Citations: 46     Fields:    Translation:AnimalsCells
    131. Du L, Zhao G, Lin Y, Sui H, Chan C, Ma S, He Y, Jiang S, Wu C, Yuen KY, Jin DY, Zhou Y, Zheng BJ. Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection. J Immunol. 2008 Jan 15; 180(2):948-56. PMID: 18178835.
      Citations: 67     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    132. Du L, He Y, Jiang S, Zheng BJ. Development of subunit vaccines against severe acute respiratory syndrome. Drugs Today (Barc). 2008 Jan; 44(1):63-73. PMID: 18301805.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    133. Zhu Z, Chakraborti S, He Y, Roberts A, Sheahan T, Xiao X, Hensley LE, Prabakaran P, Rockx B, Sidorov IA, Corti D, Vogel L, Feng Y, Kim JO, Wang LF, Baric R, Lanzavecchia A, Curtis KM, Nabel GJ, Subbarao K, Jiang S, Dimitrov DS. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci U S A. 2007 Jul 17; 104(29):12123-8. PMID: 17620608.
      Citations: 151     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    134. Du L, Kao RY, Zhou Y, He Y, Zhao G, Wong C, Jiang S, Yuen KY, Jin DY, Zheng BJ. Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity. Biochem Biophys Res Commun. 2007 Jul 20; 359(1):174-9. PMID: 17533109.
      Citations: 56     Fields:    Translation:HumansCells
    135. Du L, Zhao G, He Y, Guo Y, Zheng BJ, Jiang S, Zhou Y. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Vaccine. 2007 Apr 12; 25(15):2832-8. PMID: 17092615.
      Citations: 89     Fields:    Translation:AnimalsCells
    136. Du L, He Y, Wang Y, Zhang H, Ma S, Wong CK, Wu SH, Ng F, Huang JD, Yuen KY, Jiang S, Zhou Y, Zheng BJ. Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines. Virology. 2006 Sep 15; 353(1):6-16. PMID: 16793110.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    137. He Y, Li J, Heck S, Lustigman S, Jiang S. Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design. J Virol. 2006 Jun; 80(12):5757-67. PMID: 16731915.
      Citations: 63     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    138. He Y, Li J, Li W, Lustigman S, Farzan M, Jiang S. Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. J Immunol. 2006 May 15; 176(10):6085-92. PMID: 16670317.
      Citations: 62     Fields:    Translation:HumansAnimalsCells
    139. He Y, Li J, Du L, Yan X, Hu G, Zhou Y, Jiang S. Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine. Vaccine. 2006 Jun 29; 24(26):5498-508. PMID: 16725238.
      Citations: 31     Fields:    Translation:AnimalsCells
    140. He Y, Li J, Jiang S. A single amino acid substitution (R441A) in the receptor-binding domain of SARS coronavirus spike protein disrupts the antigenic structure and binding activity. Biochem Biophys Res Commun. 2006 May 26; 344(1):106-13. PMID: 16615996.
      Citations: 14     Fields:    Translation:AnimalsCells
    141. He Y, Zhou Y, Siddiqui P, Niu J, Jiang S. Identification of immunodominant epitopes on the membrane protein of the severe acute respiratory syndrome-associated coronavirus. J Clin Microbiol. 2005 Aug; 43(8):3718-26. PMID: 16081901.
      Citations: 35     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    142. Jiang S, He Y, Liu S. SARS vaccine development. Emerg Infect Dis. 2005 Jul; 11(7):1016-20. PMID: 16022774.
      Citations: 90     Fields:    Translation:HumansCells
    143. MacDonald AJ, Cao L, He Y, Zhao Q, Jiang S, Lustigman S. rOv-ASP-1, a recombinant secreted protein of the helminth Onchocercavolvulus, is a potent adjuvant for inducing antibodies to ovalbumin, HIV-1 polypeptide and SARS-CoV peptide antigens. Vaccine. 2005 May 16; 23(26):3446-52. PMID: 15837368.
      Citations: 14     Fields:    Translation:AnimalsCells
    144. He Y, Lu H, Siddiqui P, Zhou Y, Jiang S. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol. 2005 Apr 15; 174(8):4908-15. PMID: 15814718.
      Citations: 126     Fields:    Translation:HumansAnimalsCells
    145. He Y, Zhu Q, Liu S, Zhou Y, Yang B, Li J, Jiang S. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines. Virology. 2005 Mar 30; 334(1):74-82. PMID: 15749124.
      Citations: 57     Fields:    Translation:HumansAnimalsCells
    146. He Y, Jiang S. Vaccine design for severe acute respiratory syndrome coronavirus. Viral Immunol. 2005; 18(2):327-32. PMID: 16035944.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    147. He Y, Zhou Y, Siddiqui P, Jiang S. Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry. Biochem Biophys Res Commun. 2004 Dec 10; 325(2):445-52. PMID: 15530413.
      Citations: 65     Fields:    Translation:AnimalsCells
    148. He Y, Zhou Y, Liu S, Kou Z, Li W, Farzan M, Jiang S. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun. 2004 Nov 12; 324(2):773-81. PMID: 15474494.
      Citations: 183     Fields:    Translation:HumansAnimalsCells
    149. He Y, Zhou Y, Wu H, Kou Z, Liu S, Jiang S. Mapping of antigenic sites on the nucleocapsid protein of the severe acute respiratory syndrome coronavirus. J Clin Microbiol. 2004 Nov; 42(11):5309-14. PMID: 15528730.
      Citations: 24     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    150. He Y, Zhou Y, Wu H, Luo B, Chen J, Li W, Jiang S. Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines. J Immunol. 2004 Sep 15; 173(6):4050-7. PMID: 15356154.
      Citations: 67     Fields:    Translation:HumansAnimalsCells
    151. Zhang JJ, Wu SY, Xu W, Hou JL, Wang ZH, Jiang SB, Wu SG. [Immunological reaction between the peptides from S1 domain of SARS coronavirus S-protein and the serum from SARS patients]. Di Yi Jun Yi Da Xue Xue Bao. 2004 Jul; 24(7):789-90, 797. PMID: 15257904.
      Citations:    Fields:    Translation:HumansCells
    152. Ding Y, He L, Zhang Q, Huang Z, Che X, Hou J, Wang H, Shen H, Qiu L, Li Z, Geng J, Cai J, Han H, Li X, Kang W, Weng D, Liang P, Jiang S. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J Pathol. 2004 Jun; 203(2):622-30. PMID: 15141376.
      Citations: 420     Fields:    Translation:HumansCells
    153. Liu S, Xiao G, Chen Y, He Y, Niu J, Escalante CR, Xiong H, Farmar J, Debnath AK, Tien P, Jiang S. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet. 2004 Mar 20; 363(9413):938-47. PMID: 15043961.
      Citations: 197     Fields:    Translation:HumansCells
    Jiang's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (534)
    Explore
    _
    Co-Authors (424)
    Explore
    _
    Similar People (60)
    Explore
    _